Clinical trial
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
NCT00303862 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00303862 |
|---|---|
| Title | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer |
| Official title | A Phase 2 Study of AZD2171 in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis |
| Enrollment | 10 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Mar 17, 2006 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: